A study compared the concordance between participant and clinician assessment of eligibility for rosuvastatin 5 mg using an at-home web-based application.

Achieving LDL-c target, measurements of risk factors, and a need for tailored therapy choices are three important factors to reduce (residual) CV risk. Prof. Stroes briefly discusses these three topics.

A cost-effectiveness study suggests that population genomic screening for FH in young adults could be cost-effective from a healthcare perspective and cost-saving from a societal perspective at testing costs that are feasible.

Many questions remain on the subject of triglycerides, EPA-based therapies and CV outcomes. Three discussants attempt to unravel the mysteries in this field.

In this e-learning program, three experts explain why it is important to measure Lp(a) levels. Furthermore, they describe the effects of currently available lipid-lowering treatments on Lp(a) levels and talk about potential therapies for Lp(a) lowering which are currently under investigation.

Prof. Stroes describes the effects of currently available lipid-lowering treatments on Lp(a) levels. Futhermore, he talks about potential RNA-based therapies for Lp(a)-lowering, which are currently under investigation.

A coronary artery calcium-guided statin treatment protocol in asymptomatic participants with a family history of premature CAD led to a reduction in a predicted 10-year CV risk score, compared to usual care.

Real-world evidence shows that the majority of patients do not achieve their LDL-c target goals. Where do we fall short in the need for combination therapy?

Prof. Kronenberg talks about the epidemiology and genetic basis of Lp(a) levels and explains why and when Lp(a) should be measured.

ESC 2021 Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

Prof. Ray explains why monotherapy is not sufficient, and thus combination therapy is needed to reach LDL-c goals in patients with high CV risk.

ESC 2021 The SANTORINI study aims to investigate whether the 2019 ESC/EAS guidelines for the management of dyslipidemia are being implemented across Europe.